~ WEBINAR ~
Controversies of Fatty Liver Disease:
Diagnosis & Treatment in Pediatric Patients
TO ENTER THE WEBINAR:
Please review the following information, scroll down to the bottom of the page and click on the "Launch Webinar Now" link. This 62-minute webinar was recorded live on April 24, 2013. CME expiration date: April 23, 2016.
Thank you for joining NASPGHAN and the NASPGHAN Foundation for a live one-hour CME webinar on the latest scientific information regarding Controversies of Fatty Liver Disease. The webinar will be archived on the NASPGHAN Foundation website following the program. NASPGHAN designates this educational activity for a maximum of 1.25 AMA PRA Category 1 CME Credits.™
Supported by Synageva BioPharma.
Rohit Kohli, MBBS, MS
Associate Professor of Pediatrics, Metabolic Diseases Institute,
University of Cincinnati
Co-Director, Cincinnati Children's Steatohepatitis Center
Pediatric Liver Care Center
Cincinnati Children's Hospital Medical Center
Miriam Vos, MD, MSPH
Assistant Professor of Pediatrics
Stavra Xanthakos, MD, MS
Co-Director, Cincinnati Children’s Steatohepatitis Clinic
Medical Director, Surgical Weight Loss Program for Teens
Associate Professor Pediatrics
Division of Gastroenterology, Hepatology and Nutrition
Cincinnati Children’s Hospital Medical Center
University of Cincinnati College of Medicine
Jeffrey B. Schwimmer, MD
Professor of Pediatrics
Director, Weight and Wellness
Director, Fatty Liver Clinic
Rady Children's Hospital
Division of Gastroenterology, Hepatology, and Nutrition
Department of Pediatrics
University of California, San Diego
San Diego, CA
Stephanie H. Abrams, MD, MS
Assistant Professor of Pediatrics
Baylor College of Medicine/Texas Children's Hospital
Gastroenterology, Hepatology, & Nutrition
Medical Director Fatty Liver Clinic
Almost a fifth of our general pediatric population is now classified as obese in the United States. Obesity related fatty liver disease or nonalcoholic fatty liver disease (NAFLD) has been recognized for more than two decades now. Today when children that are obese present with elevated liver enzymes the most common diagnosis is obesity related fatty liver disease or NAFLD.
Long term follow up studies show that NAFLD can progress in a minority of children to the more severe form of the disease that has inflammation and fibrosis (nonalcoholic steatohepatitis or NASH). NASH patients can progress to cirrhosis as older adults and sometimes even in adolescence. Liver biopsy is the current gold standard for accurate diagnosis and evaluation of fibrosis progression in patients with NAFLD/NASH.
However, the invasive nature and inherent risk of percutaneous liver biopsy have resulted in a dilemma for the practicing physician. Treatment options for NASH outside of lifestyle modifications and weight loss again are limited, though Vitamin E has recently been highlighted as a potential therapeutic option.
This webinar will provide an update on screening, diagnosis and effective treatment options for pediatric NAFLD to help learners implement optimal strategies into their clinical practice.
This activity is designed for gastroenterologists, primary care physicians, physician assistants, nurse practitioners, trainees, dieticians, and other health care professionals who are involved in the care of pediatric patients.
• List the most common demographics of patients with fatty liver disease
• Describe the constellation of signs and symptoms associated with fatty liver disease
• Perform appropriate testing when fatty liver disease is suspected
• Describe the appropriate treatment methods
• Appropriately refer patients to liver specialists
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and the NASPGHAN Foundation. NASPGHAN is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA STATEMENT
NASPGHAN designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Completion of this CME activity involves the viewing of the slide set and completion of the posttest and evaluation form.
All faculty/speakers, planners, abstract reviewers, moderators, authors, coauthors, and administrative staff participating in the continuing medical education programs sponsored by NASPGHAN and NASPGHAN Foundation, are expected to disclose to the program audience any/all relevant financial relationships related to the content of their presentation(s). Accordingly, the staff at NASPGHAN and NASPGHAN Foundation has reported no financial relationships with any commercial interests related to the content of this educational activity.
• Drs. Kohli, Vos, Xanthakos, Schwimmer and Abrams have nothing to disclose.
In accordance with ACCME Standards for Commercial Support of CME, NASPGHAN and NASPGHAN Foundation implemented mechanisms to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity. To resolve identified conflicts of interest, the educational content was peer-reviewed by a physician member of the NASPGHAN Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.
DISCLOSURE OF UNLABLED OR INVESTIGATIONAL DRUGS
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
This activity will consist of a web-based application where the participants access the meeting by clicking on a link distributed by e-mail (meeting invitation) to enter the conference. Participants will need speakers or an audio headset to listen to the webinar. If you encounter problems, please notify us at firstname.lastname@example.org
RECEIVING CME CREDIT
To receive CME credit for reviewing this activity, participants must review the CME information (learning objectives, disclosures, etc.), review the entire activity, and complete the activity posttest and evaluation questions. To complete the activity posttest and evaluation, please visit this web page.
Certificates will be provided immediately after completion of both posttest and evaluation. If you have questions about receiving credit: Please e-mail email@example.com
Jointly sponsored by NASPGHAN and NASPGHAN Foundation
For questions, please contact:
PO Box 6 Flourtown, PA 19031
Phone: (215) 233-0808 Fax: (215) 233-3918
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of NASPGHAN, NASPGHAN Foundation, Synageva BioPharma. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
POLICY ON PRIVACY AND CONFIDENTIALITY
NASPGHAN, and NASPGHAN Foundation, will make every effort to protect the privacy of every individual participant of this activity and will use information gathered only to maintain records as required by the American Medical Association (AMA) and ACCME. This activity does not require readers to “register” to review the material with the exception of physicians and other health care providers who desire to receive CME credit for this accredited activity. If an individual completes a CME for this accredited activity, we are required by the AMA and ACCME to collect personal information on the individual, such as their name, address, and phone number, that will allow us to issue a CME certificate to them and to keep this information on file for up to 6 years. Personal information gathered will not be released to any other company or organization for any purpose. This information remains totally confidential.
PC or Mac, a high-speed Internet connection, speakers, and Flash 10 required. To download Flash, go here
© 2013 NASPGHAN and NASPGHAN Foundation
Produced by Limelight Communications